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mode of action and have activity against methicillin-resistant Slaphylococcus
aureus, penicillin-resistant pneumococci and vancomycin-resistant entero-
cocci. Other novel antibiotics arc being developed through chemical
modification ofexisting agents. such as the alteration of the ftuoroquinolone
nucleus or synthesis ofa glycopeptide related to vancomycin. Bacteriophage
therapy is being developed to treat multiply resistant E1Ilao(Occus faecium
infections. Furthermore, antisense constructs used alone or as adjuncts to
bacteriophage therapy maybe useful for reversing vancomycin resistance.
Thus. many approaches are being investigated to combat increasing levels of
multiresistant Gram-positive bacteria.
ITu19-sl Meningitis: Consequences of resistance on the choice
of treatment
K. P. Klugman
Pneumococcal Diseases Research Unit, Johanllesburg, South Africa
The empirical management ofbacterial meningitis has changed over the past
decade as a direct result of decreasing susceptibility to antimicrobials by the
major bacterial causes ofthis disease. Ampicillin and chloramphenicol can no
longer be considered for initial therapy; pneumococci are increasingly
resistant to penicillins worldwide, and chloramphenicol-resistance remains
common in developing countries. Resistance is rapidly spreading through
the dissemination of multi-resistant pneumococcal clones. Pneumococci
have also acquired resistance to the third-generation cephalosporins, cefo-
taxime and ceftriaxone. Where cephalosporin resistance is known to occur.
the addition of vancomycin should be considered. Strains of Neisseria
mellillgilidis resistant to chloramphenicol have emerged. as have strains
with intermediate penicillin-resistance. The incidence of chloramphenicol-
resistant strains of Hannophilus il!fiuenzae has increased in frequency in
Africa. and betalaetamase producing strains remain common worldwide.
Gram-negative bacteria and Listtria (isolated more rarely in meningitis) also
exhibit multiresistance to cephalosporins. Thus there is an urgent need for
more active drugs for the trearment of meningitis. The carbapenerns have
enhanced in vitro activity against bacterial pathogens compared with the
third-generation cephalosporins. Three randomised comparative trials have
compared meropenem with cefotaxime and/or ceftriaxone in bacterial
meningitis. Meropenem was as clinically efficacious and as well tolerated
as the cephalosporins in these studies. Furthermore, to date there have been
no bacteriologically documented failures of meropenem in cephalosporin-
resistant pneumococcal meningitis. Current empiric management ofmenin-
gitis is based on the use ofcefotaxime or ceftriaxone plus vancomycin. With
increasingly widespread resistance to existing antimicrobial agents, mono-
therapy with meropenem represents an alternative tre.atnl':nt regim.en.
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ITUI14-1I Control of hospital acquired bacterial resistance:
Implications for empiric therapy selection
M. J. Struelens. B. Byl, J. L. Vincent
Unive,site Libre de Bruxelles, Hopilal Erasme, Brussels, Belgium
Increasing antibiotic resistance ofbacterial pathogens is limiting the options
for empiric therapy of nosocomial infection. Resistance increases as a result
of selection of resistant mutants. acquisition of mobile resistance determi-
nants and epidemic spread ofmulti-resistant clones. The selection pressure of
antibiotic use contributes to all these mechanisms so that interventions aimed
at reducing or modulating this selective pressure through antibiotic policy
are currently evaluated. In a number of settings. both hospital-wide or in
intensive care or oncology department, restriction of prescription of
frequently used agents like third generation cephalosporins or ftuoroquino-
lones have been attempted to control resistance to these drugs ofnosocomial
Gram-negative rods. including Klebsiella spp. ElIlerobaCler spp and Acineto-
baCler spp. In several studies. this policy. with or without additional infection
control measures. appeared effective in reducing the incidence of coloniza-
tion or infection with multi-resistant strains. In our tertiary care center in a
country where multi-resistant ElIlerobaCler aerogenes has become endemic, we
performed an antibiotic policy intervention in the department of intensive
care to reduce the incidence ofMR-E. aerogenes colonization. Compared to a
6-month baseline. the use of third generation cephalosporins was reduced in
the 32-month intervention period by 82%. that offtuoroquinolones by 86%
and cefepime was added to the formulary for empiric therapy. We observed
a significant and persistent reduction in the resistance of Enrerobacleriaceae
(but not of Pseudomonas aeruginosa) to these drugs as well as • significant
reduction in the incidence rate of MR-E. aerogenes. These data illustrate the
usefulness ofadapting empiric policy regimens in high-risk hospital units to
improve the local ecology ofresistance. A rotation strategy may represent a
worthwhile option.
[ThI14-2ICefepime for multiple antibiotic resistant GNR
infections
M.Joshi l • R. Brul11• N. Sompalil • S. Qaiyurni.J. A.Johnson
IRA Cowley Shock Trauma Cmler, Ballimore, USA
Third-generation cephalosporins (3C) were considered first-line antibiotics
for treating serious gram-negative rod (GNR) infections. Recently. expres-
sion of AmpC cephalosporinase (AmpC) and extended spectrum ~lacta­
rna.., (ESBL) in GNR has resulted in widespread resistance to 3C. Cefepime.
the new cephalosporin. requires two distinct mutational events for devel-
opment of resistance. thereby decreasing the likelihood of resistance.
Although in vitro data demonstrates the enhanced activity of cefepime
against these strains. clinical data is bcking.
Methods: In an 18-month retrospective study. we identified 14 patients
treated with cefepime for resistant GNR infections. CDC guidelines were
used to identify infection. GNR included in the study had diminished zones
of inhibition around 3C. aztreonam. and cefpodoxime disks. Ten of the 14
p.thogens were screened for ESBl production by NCClS guidelines.
Clavulate-resistant strains may carry AmpC.
Results: The mean length ofstay was 45.4 days. prior antibiotics were used
in 12 patients. the mean age of the patients was 52.4 years of age. the male:
female ratio was 8:6. and the mean day of GNR acquisition was 26.4. The
infection sites included pulmonary (4 p), skin and soft tissue (5 p). and CSF/
Bone/BloodJIAA/Urine (5 pl.
No. ESBl/
Pathogens patient' AmpC Outcomes Clinical Bacterial
K pneumoniae 5 3/1 Cure 11 13
K oxytoca 2 I/O failure 1 0
Not evalu-
E coli 2 2/0 able 2
E cloacae 5 0/3
Condusions: Cefepime was effective in a small number ofpatients. Larger
studies arc needed to confirm these results.
!TuI14-3I Empiric therapy of nosocomial pneumonia in
intensive care unit patients
G. Zanetti
Ha"'ard University, Boslon, Uniled S,a'es
Early appropriate antibiotic therapy diminishes mortality in intensive care
unit (ICU) patients with nosocomial pneumonia. However. the poor
specificity ofclinical and microbiological diagnosis ofnosocomial pneumo-
nia and the wide array of possible pathogens make the empiric choice of
antibiotics difficult. Monotherapy with broad-spectrum antibiotics recently
emerged as an appealing option.
Objective: To compare the efficacy of cefepime. 2 g three times a day. and
imipenem/cilastatin. 0.5 g four times a day. as monotherapy for ICU patients
with nosocomial pneumonia.
Methods: The randomized. open-label. evaluator-blind study was con-
ducted in 13 centers from six European countries. Sixty-six percent of the
270 eligible patients had mechanical ventilation. The mean APACHE II
score was 16 at randomization.
Results: Microbiological documentation was available for 180 patients
(67%). The most frequent causative organism was Pseudomonas aeruginosa,
which occurred in 70 patients. In each group. 86% ofthe causative organisms
were susceptible to the allocated regimen. Success rate (cure or improve-
ment) in intent-to-treat analysis was similar with cefepime (59%) and
imipenem/cilastatin (57%). Clinical failure was attributed to resistance of
the causative organism in 5.3% of the cefepime patients and 5.8% of the
imipenem/cilastatin patients. Among microbiologically documented noso-
comial pneumonia. eradication rates were 52% with cefepime and 44% with
imipenem/cilastatin. Resistance to the allocated regimen occurred in 4.1 %
of the causative organisms in cefepime and 6.9% ofthe causative organisms
in imipenem/cilastatin. Nosocomial pneumonia contributed to the death of
11 patients in cefepime .nd eight patients in imipenem/cilastatin.
Clinical Microbiology and Infection, Volume 6 Supplement 1, May 2000 249
Condusion: We concluded that cefepime and imipenemfcilastatin were
active against most of the pathogens causing nosocomial pneumonia in
ICU patients and ware clinically equally effective for monotherapy.
[TUfI4N4] Febrile neutropenia-role and evolution of
monotherapy
R. Ramphal
University ofF/orida, Gainesl,ille, Utlited States
Patients with febrile neutropenia have become a significant population in
large and specialized medical centers. They comprise a heterogeneous group
ofpatients that have different prognoses and risks for infection. Solid tumor
and lymphoma patients make up the largest number of this group followed
by leukemia patients, and bone marrow ur stem cell transplantation patients.
The prognosis of all patients with febrile neutropenia has improved
significantly over the past 20 years despite more aggressive therapies for
malignancy. Antibiotics have been the most signifieant improving factor.
Antibacterial therapy has improved in treatment approaches and the avail-
able drugs. Combination therapy with a /3-lactam and an aminoglycoside
has been a standard ofcare since the introduction ofcarbenicillin in the 1970s.
This approach was replaced by more potent antipseudomonal and anti
gram-negative drugs. In some areas, ceftazidime or imipenem monotherapy
became interchangeable with combination therapy. Certain factors are now
driving the evolution of therapy to newer agents, including bacterial
resistance and changes in organisms cultured from infections. However,
the case for continued monotherapy is stronger because of the introduction
of cefepime, fourth-generation cephalosporin. with improved gram-posi-
tive and gram-negative activity over ceftazidime and meropenem, a
carbapenem. The outpatient use of antibiotics is another direction to
manage these patients. Accumulating evidence indicates that patients at
lower risk for infection (eg, those with a shorter anticipated duration of
neutropenia), may be managed as outpatients and oral antibiotics may be
safe. It appears that maximum doses ofantibiotics as used in the past may not
be needed. The role offluoroquinolones in this group of patients has clearly
been established and newer agents may expand their use. The antibiotic
management of febrile neutropenia should include risk determination,
knowledge of prevailing resistance patterns and the epidemiology of
infections in the institution.
ITuI14-SI New alternatives in the empiric treatment of
meningitis and other serious pediatric infections
D. Kafetzis
A.l1laia Children's Hospital, Athens, Greece
Hospital-acquired bacterial infections represent a key cause of substantial
morbidity and mortality among the pediatric population. It is estimated that
almost 10% of hospitalized patients in the United States and Europe will
develop an infection during their hospital stay. The most common nosoco-
nJal infections afflicting pediatric patients are hospital-acquired pneumonia,
urinary tract infections, blood stream infections, and surgical site infections.
Pediatric neutropenic patients are prone to developing bacterial infections.
Treatment is often a challenge and requires initiation of empirical therapy
with a broad-spectrum antibiotic. Bacterial meningitis is another cause of
many pediatric intensive care unit admissions. Cefepime is a fourth-genera-
tion cephalosporin with excellent in vitro and in vivo activity against
pathogens that are commonly implicated in serious pediatric infections.
Cefepime has been shown to be as safe and effective as ceftazidime,
cefotaxime, and cefuroxime in the treatment of lower respiratory tract
infections. There was a clinical response rate in 88% to 100% of patients. In
patients with urinary tract infections, primarily caused by E coli and Proteus
species, cefepime 50 mg/kg/dose every 8-12 hours has been as effective and
safe as ceftazidime exhibiting clinical cure and bacteriologic eradication rates
above 90%. In pediatric patients with febrile neutropenin, cefepime has
shown comparable efficacy rates to ceftazidime. Patients treated with
cefepime developed fewer new infections and required less concomitant
systemic antimicrobial therapy than ceftazidime. In several trials conducted
in Europe and Latin America, patients with bacterial meningitis had similar
cure rates compared to those who were treated with eefotaxime and
ceftriaxone. Eradication rates of the most commonly isolated pathogens,
H influenzae, N meningitidis, and S pneumoniae, were above 90%.
Cefepime has a favorable safety and pharmacokinetic profile allowing for
twice-daily or thrice-daily administration depending on the severity of
infection. It has adequate tissue penetration and excellent activity against
gram-positive and gram-negative pathogens often implicated in serious
pediatric infections. Cefepime is an ideal choice for the empiric treatment of
pediatric patients.
IND15 - Berna Products: Virosome vaccines: advantages
in safety •••
ITu11S-11 The virosome vaccine principle
JanWilschut
Laboratory ofMolecular Virology, Department ofMedical Microbiology,
University of Gronin.l1en and Academic Hospital, Ant. Deusinglaan 1, 9713 A V
Gronin.l1en, Netherlands
Induction of an effective immune response by vaccination requires a proper
processing and presentation of the vaccine antigen by antigen-presenting
cells (APCs). Virosomes, derived from, e.g., influenza virus, represent a
promising carrier system for delivery of antigens to APCs. Virosomes are
reconstituted viral envelopes which can be generated from native virus
through a detergent solubilization and removal procedure. Antigenic pep-
tides or proteins may be encapsulated in the virosomal lumen by including
them in the reconstitution mixture prior to the detergent removal step.
Antigens may also be coupled to the surface of the virosomes.
Functionally reconstituted virosomes retain the cell entry and membrane
fusion characteristics of the native virus. Thus, influenza-derived virosomes
enter cells, including APCs, through receptor-mediated endocytosis and
subsequent fusion from within acidic endosomes. In this manner, virosome-
encapsulated antigens are released into the cell cytosol and, thus, into the
MHC class I antigen processing pathway. On the other hand, antigens
associated with the virosomal surface are introduced into the endosomal
membrane, facilitating their processing in the MHC class n presentation
pathway.
We have studied the capacity of influenza virosomes to prime class I
MHC-restricted cytotoxic T lymphocyte (CTL) activity in mice against a
peptide or whole-protein antigen. An efficient CTL response was induced
with virosomes containing a synthetic peptide corresponding to a CTL
epitope of the influenza nucleoprotein or containing the protein ovalbumin.
The superior antigen-delivery capaciry ofvirosomes is primarily due to their
membrane fusion activity, since fusion-inactivated antigen-containing viro-
somes lack the ability to efficiently prime CTL activity.
ITul15-21 Influenza vlrosomes to fight Influenza?
J. Oxford
Department of Medical Microbiology. St. Bartholomew's and The Royal
London School ofMedicitle and Dentistry, London, United Kingdom
Influenza vaccine will remain the cornerstone in the clinical management of
influenza alongside new developments in anti NA inhibitors. The current
influenza vaccines prevent hospitalization and mortality in the elderly and 'at
risk' vaccine groups. However, a low proportion ofelderly are non or poor
responders to vaccine. Therefore, new adjuvants are urgently required.
The in vivo ferret model data will be presented which establishes that
influenza virosome formulations have high efficacy in preventing influenza
virus excretion and clinical symptoms. Moreover intranasal administration
of virosome vaccine induces circulatory IgG antibody to influenza. Recent
clinical studies of virosomes in volunteers will also be presented in the above
context.
ITuI1S-3! Clinical experience with an inactivated virosome
fonnulatec:l hepatitis A vaccine
P. Bovier'. L. Loutan'. F. Ambrosch2, R. GliickJ , C. HerzogJ
'Department l.Community Medicine, University Hospital, Geneva,
Switzerland; Institute for Specif,c Prophylaxis & Tropical Medicine,
University of Vienna, Austria; Swiss Serum and Vaccine Institute, Berne,
Switzerland
Ten years of clinical experience with the aluminium-free, virosome for-
mulated. inactivated hepatitis A vaccine (500 RIA units) are summarised.
Data are presented on the dosing regimen (months 0, 12), on safety and
immunogenicity (also in comparison to an aIuminium-ad!lOrbed vaccine),
on potential interactions with other vaccines, on use in children and in
